Ironwood Pharmaceuticals, Inc. (IRWD) financial statements and ratios from SEC XBRL: revenue $0.5B (TTM), net margin 8.1%, revenue growth -15.7% YoY, P/E 4.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $296.15M |
| Revenue (TTM) | $0.5B |
| Net Margin | 8.1% |
| Operating Margin (TTM) | 73.9% |
| Net Debt / EBITDA | 0.2 |
| Revenue Growth (YoY) | -15.7% |
| EPS Growth (YoY) | 1400.0% |
| FCF Growth (YoY) | 22.8% |
| P/E Ratio | 4.1 |
| EV / EBITDA | 2.1 |
| Price / Sales | 1.58 |
| FCF Yield | 7.4% |
| Altman Z-Score | -3.61 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
IRWD overview · IRWD earnings · IRWD KPIs · IRWD documents · IRWD ownership · IRWD peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.